Venture Report: Blackstone eyes pipeline-in-a-product via Uniquity launch

An immunology start-up emerged from stealth with a large commitment from Blackstone, and two firms announced new funds this week to foster biotech start-ups’ growth.

Blackstone Life Sciences has committed up to $300 million to newly launched Uniquity Bio Inc., a company advancing an antibody that could  have advantages over others in the anti-TSLP class to treat immune and inflammatory diseases, starting with COPD and asthma...